Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00666471

Minimally Invasive Control of Epistaxis (MICE) (MICE)

Minimally Invasive Control of Epistaxis: Efficacy and Economic Analysis

Sponsor: University of Calgary

Conditions Epistaxis

Updated 9 times since 2017 Last updated: Jun 10, 2009 Started: Jun 30, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

one PI (BM) no longer felt he had clinical equipoise regarding the intervention. No adverse events.

This PHASE2/PHASE3 trial investigates Epistaxis and is currently terminated or withdrawn. University of Calgary leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2_PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 4 earlier versions

Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2_PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Calgary

Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Calgary, Canada